On February 6, 2020 AkesoBio, a Zhongshan novel drug discovery and development biopharma, reported that it filed for a $300 million Hong Kong IPO to develop its portfolio of novel mono- and bi-specific antibodies (Press release, Akeso Biopharma, FEB 6, 2020, View Source [SID1234553999]). The company has built a portfolio of 18 mAbs that are in either CMC or clinical stages of development for oncology, inflammation, autoimmune and cardiovascular diseases. In general, Akeso develops bispecific antibodies using a PD-1 antibody as a backbone. Late last year, Akeso Biopharma closed a $150 million Series D round of financing led by Loyal Valley Capital and Sino Biopharm.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!